Genzyme and Merck agree cancer assay licence:
This article was originally published in Clinica
Executive Summary
Genzyme Molecular Oncology has licensed non-exclusive rights to Merck for Genzyme's methods of assaying small molecule compounds for their action against the cancer-related protein, MDM2. Merck will pay up to $8 million in milestone payments if it can develop a therapeutic product through use of this assay.